Jason Aryeh - Net Worth and Insider Trading
Jason Aryeh Net Worth
The estimated net worth of Jason Aryeh is at least $9 Million dollars as of 2024-04-23. Jason Aryeh is the Director of Ligand Pharmaceuticals Inc and owns about 123,822 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $8 Million. Jason Aryeh is the Director of Novelion Therapeutics Inc and owns about 392,733 shares of Novelion Therapeutics Inc (NVLNF) stock worth over $275,699. Jason Aryeh is also the See Explanation of Responses of Merrimack Pharmaceuticals Inc and owns about 3,802 shares of Merrimack Pharmaceuticals Inc (MACK) stock worth over $56,003. Besides these, Jason Aryeh also holds Myrexis Inc (MYRX) . Details can be seen in Jason Aryeh's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jason Aryeh has not made any transactions after 2019-09-03 and currently still holds the listed stock(s).
Transaction Summary of Jason Aryeh
Jason Aryeh Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jason Aryeh owns 10 companies in total, including Ligand Pharmaceuticals Inc (LGND) , Merrimack Pharmaceuticals Inc (MACK) , and Old API Wind-down Ltd (ARLZQ) among others .
Click here to see the complete history of Jason Aryeh’s form 4 insider trades.
Insider Ownership Summary of Jason Aryeh
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
LGND | Ligand Pharmaceuticals Inc | 2019-09-03 | director |
MACK | Merrimack Pharmaceuticals Inc | 2019-07-16 | 10 percent owner & other: See Explanation of Responses |
ARLZQ | Old API Wind-down Ltd | 2017-05-19 | director |
NVLNF | Novelion Therapeutics Inc | 2017-05-15 | director |
IMMU | Immunomedics Inc | 2017-01-08 | director |
MYRX | Myrexis Inc | 2012-06-18 | director |
VXRT | Vaxart Inc | 2006-10-18 | other: See Remarks Below |
ANEB | Anebulo Pharmaceuticals Inc | 2022-04-21 | director |
HSAQ | Health Sciences Acquisitions Corp 2 | 2023-01-26 | director |
OBIO | Orchestra BioMed Holdings Inc | 2023-07-20 | director |
Jason Aryeh Latest Holdings Summary
Jason Aryeh currently owns a total of 4 stocks. Among these stocks, Jason Aryeh owns 123,822 shares of Ligand Pharmaceuticals Inc (LGND) as of September 3, 2019, with a value of $8 Million and a weighting of 96.18%. Jason Aryeh owns 392,733 shares of Novelion Therapeutics Inc (NVLNF) as of May 15, 2017, with a value of $275,699 and a weighting of 3.12%. Jason Aryeh also owns 3,802 shares of Merrimack Pharmaceuticals Inc (MACK) as of July 16, 2019, with a value of $56,003 and a weighting of 0.63%. The other 1 stocks Myrexis Inc (MYRX) have a combined weighting of 0.07% among all his current holdings.
Latest Holdings of Jason Aryeh
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
LGND | Ligand Pharmaceuticals Inc | 2019-09-03 | 123,822 | 68.61 | 8,495,427 |
NVLNF | Novelion Therapeutics Inc | 2017-05-15 | 392,733 | 0.70 | 275,699 |
MACK | Merrimack Pharmaceuticals Inc | 2019-07-16 | 3,802 | 14.73 | 56,003 |
MYRX | Myrexis Inc | 2012-06-18 | 555,145 | 0.01 | 5,829 |
Holding Weightings of Jason Aryeh
Jason Aryeh Form 4 Trading Tracker
According to the SEC Form 4 filings, Jason Aryeh has made a total of 7 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years, including 7 buys and 0 sells. The most-recent trade in Ligand Pharmaceuticals Inc is the acquisition of 750 shares on September 3, 2019, which cost Jason Aryeh around $65,258.
According to the SEC Form 4 filings, Jason Aryeh has made a total of 0 transactions in Novelion Therapeutics Inc (NVLNF) over the past 5 years. The most-recent trade in Novelion Therapeutics Inc is the acquisition of 361 shares on May 15, 2017, which cost Jason Aryeh around $3,231.
According to the SEC Form 4 filings, Jason Aryeh has made a total of 2 transactions in Merrimack Pharmaceuticals Inc (MACK) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Merrimack Pharmaceuticals Inc is the acquisition of 302 shares on July 16, 2019, which cost Jason Aryeh around $1,643.
More details on Jason Aryeh's insider transactions can be found in the Insider Trading History of Jason Aryeh table.Insider Trading History of Jason Aryeh
- 1
Jason Aryeh Trading Performance
GuruFocus tracks the stock performance after each of Jason Aryeh's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jason Aryeh is 4.93%. GuruFocus also compares Jason Aryeh's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jason Aryeh within 3 months outperforms 21 times out of 37 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jason Aryeh's insider trading performs compared to the benchmark.
Performance of Jason Aryeh
Average Return
-3.85%
Outperforming Transactions
57%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 6.23 | 4.93 | 9.04 | -3.85 | -8.27 | -0.04 |
Relative Return to S&P 500(%) | 4.57 | 0.47 | 3.33 | -17.4 | -24.86 | -14.13 |
Jason Aryeh Ownership Network
Ownership Network List of Jason Aryeh
Ownership Network Relation of Jason Aryeh
Jason Aryeh Owned Company Details
What does Ligand Pharmaceuticals Inc do?
Who are the key executives at Ligand Pharmaceuticals Inc?
Jason Aryeh is the director of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include Chief Financial Officer Octavio Espinoza , CHIEF LEGAL OFFICER & Andrew Reardon , and CEO & President John L Higgins .
Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary
Over the past 18 months, Jason Aryeh made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 20,000 shares made by John L Higgins , a net sale of 10,852 shares made by John W Kozarich , and a net sale of 8,301 shares made by Stephen L Sabba .
In summary, during the past 3 months, insiders sold 2,033 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 0 shares, with a net sale of 2,033 shares. During the past 18 months, 41,289 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 37,289 shares.
Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ligand Pharmaceuticals Inc Insider Transactions
Jason Aryeh Mailing Address
Above is the net worth, insider trading, and ownership report for Jason Aryeh. You might contact Jason Aryeh via mailing address: 11119 North Torrey Pines Road, Suite 200, La Jolla Ca 92037.